1. Home
  2. SIDU vs PLX Comparison

SIDU vs PLX Comparison

Compare SIDU & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sidus Space Inc.

SIDU

Sidus Space Inc.

HOLD

Current Price

$1.92

Market Cap

286.7M

ML Signal

HOLD

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

HOLD

Current Price

$2.62

Market Cap

230.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SIDU
PLX
Founded
2012
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
286.7M
230.0M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
SIDU
PLX
Price
$1.92
$2.62
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
4.7M
1.5M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
84.42
N/A
EPS
N/A
N/A
Revenue
$4,672,646.00
$53,399,000.00
Revenue This Year
N/A
$9.67
Revenue Next Year
$100.00
$23.86
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$1.34
52 Week High
$5.39
$3.19

Technical Indicators

Market Signals
Indicator
SIDU
PLX
Relative Strength Index (RSI) 40.63 44.14
Support Level $1.02 $1.39
Resistance Level $2.19 $2.66
Average True Range (ATR) 0.19 0.15
MACD 0.01 -0.07
Stochastic Oscillator 22.55 4.96

Price Performance

Historical Comparison
SIDU
PLX

About SIDU Sidus Space Inc.

Sidus Space Inc is a Space and Defense as-a-Service company focused on providing complex space hardware, satellite/spacecraft design, manufacture, launch, and data solutions for both government and commercial in-space missions for all destinations through the solar system. This includes a Space-based infrastructure of multi-mission satellites with hyperspectral, multi-spectral, and other sensors to provide monitoring services and solutions to multiple sectors and industries. The company supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Share on Social Networks: